![]() ![]() Any drug known to affect sleep-wake function.Treatment with any investigational products within 3 months before study enrollment.Other experimental medications designed to treat narcolepsy, cataplexy or any other condition.SSRIs (selective serotonin re-uptake inhibitors) and serotonin and norepinephrine re-uptake inhibitors (SNRIs).All previous dosing must not have occurred within the last year prior to entry to the study.Īny use of the following prohibited medications for the duration of the clinical study:.Patient should not have taken sodium oxybate for more than 2 weeks. ![]() Sodium oxybate helps deep sleep and improves night-time. Previous dosing must have been limited to no more than 4.5g per night Sodium oxybate can help treat cataplexy but can also help with many of the other symptoms of narcolepsy.Addition inclusion criteria per protocolĪny prior use of sodium oxybate is allowed in the study but within the following exclusions:.They must discontinue all anti cataplexy drugs.They must use the same stimulant regimen throughout the entire study period, including during screening and posttreatment periods.They must be on a stable dose of stimulants for at least 3 weeks prior to starting the screening process for this study AND.Xyrem is approved to treat narcolepsy, although it is not clear how it works. ![]() Subjects may use concomitant stimulants, but must comply with the following: 1 day ago &0183 &32 Cataplexy is not present in Type 2 narcolepsy, which tends to be less severe.
0 Comments
Leave a Reply. |